drugset / Trial / NCT00914966

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

NCT00914966

Phase 4 Completed 20 enrolled Shire
NaSingle-groupOpen-labelPrevention

Summary

The objectives of the study were: 1. To assess the safety and tolerability of escalating doses of CINRYZE. 2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates. 3. To assess the immunogenicity of CINRYZE.

Timeline

Start
2009-08-31
Primary completion
2012-05-24
Completion
2012-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject CINRYZE Protein / enzyme biologic 1500 iu Intravenous
Subject CINRYZE Protein / enzyme biologic 2000 iu Intravenous
Subject CINRYZE Protein / enzyme biologic 2500 iu Intravenous

Indications